Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
TEL AVIV, Israel, Feb. 02, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2015 before the market open, and will host a corporate update conference call and webcast on Wednesday, February 17 at 8:30 am Eastern Time.
| Conference Call & Webcast | |
| Wednesday, February 17, 2016 @ 8:30am Eastern Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Passcode: | 34475008 |
| Webcast: | http://www.alcobra-pharma.com/events.cfm |
| Replays available through March 2, 2016 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 34475008 |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
